Search research articles
Contact Us
Filters
Showing results (301-310 of 344) with videos related to
Page
of 35
Sort By:
Cancer Chemotherapy and Pharmacology
|
June 22, 2022
A phase Ib study of Oraxol (oral paclitaxel and encequidar) in patients with advanced malignancies
Wen Wee Ma, Jenny J Li, Nilofer S Azad, et al.
Frontiers in Oncology
|
July 30, 2025
Increased accrual of diverse patient populations in oncology phase I clinical trials at the University of Colorado Cancer Center
Ahmed Alsafar, Sama L Kareem, Bradley R Corr, et al.
Journal for Immunotherapy of Cancer
|
February 3, 2024
Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors
Sandip P Patel, Teresa Alonso-Gordoa, Susana Banerjee, et al.
Frontiers in Oncology
|
April 19, 2021
WEE1 Inhibition in Combination With Targeted Agents and Standard Chemotherapy in Preclinical Models of Pancreatic Ductal Adenocarcinoma
Sarah J Hartman, Stacey M Bagby, Betelehem W Yacob, et al.
Medical and Pediatric Oncology
|
September 2, 1998
Immunophenotypic study of acute lymphoblastic leukemia (a prospective study in Brazilian children)
M H de Souza, H R Diamond, M P Santos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 20, 2022
First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical Efficacy
Jennifer R Diamond, Valentina Boni, Emerson Lim, et al.
JCO Precision Oncology
|
June 29, 2023
Exceptional Response to Bromodomain and Extraterminal Domain Inhibitor Therapy With BMS-986158 in <i>BRD4-NUTM1</i> NUT Carcinoma Harboring a <i>BRD4</i> Splice Site Mutation
Michael L Cheng, Yeying Huang, Nhi Luong, et al.
BMC Cancer
|
November 5, 2020
RX-5902, a novel β-catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast Cancer
John J Tentler, Julie Lang, Anna Capasso, et al.
Journal of Applied Clinical Medical Physics
|
February 27, 2018
COMP report: CPQR technical quality control guidelines for radiation treatment centers
Kyle E Malkoske, Michelle K Nielsen, Laurent Tantôt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 24, 2013
Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinoma
Jennifer R Diamond, Ravi Salgia, Marileila Varella-Garcia, et al.
Page
of 35
Search research articles
Search
Showing results (301-310 of 344) with videos related to
Sort By:
Page
of 35
Cancer Chemotherapy and Pharmacology
|
June 22, 2022
A phase Ib study of Oraxol (oral paclitaxel and encequidar) in patients with advanced malignancies
Wen Wee Ma, Jenny J Li, Nilofer S Azad, et al.
Frontiers in Oncology
|
July 30, 2025
Increased accrual of diverse patient populations in oncology phase I clinical trials at the University of Colorado Cancer Center
Ahmed Alsafar, Sama L Kareem, Bradley R Corr, et al.
Journal for Immunotherapy of Cancer
|
February 3, 2024
Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors
Sandip P Patel, Teresa Alonso-Gordoa, Susana Banerjee, et al.
Frontiers in Oncology
|
April 19, 2021
WEE1 Inhibition in Combination With Targeted Agents and Standard Chemotherapy in Preclinical Models of Pancreatic Ductal Adenocarcinoma
Sarah J Hartman, Stacey M Bagby, Betelehem W Yacob, et al.
Medical and Pediatric Oncology
|
September 2, 1998
Immunophenotypic study of acute lymphoblastic leukemia (a prospective study in Brazilian children)
M H de Souza, H R Diamond, M P Santos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 20, 2022
First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical Efficacy
Jennifer R Diamond, Valentina Boni, Emerson Lim, et al.
JCO Precision Oncology
|
June 29, 2023
Exceptional Response to Bromodomain and Extraterminal Domain Inhibitor Therapy With BMS-986158 in <i>BRD4-NUTM1</i> NUT Carcinoma Harboring a <i>BRD4</i> Splice Site Mutation
Michael L Cheng, Yeying Huang, Nhi Luong, et al.
BMC Cancer
|
November 5, 2020
RX-5902, a novel β-catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast Cancer
John J Tentler, Julie Lang, Anna Capasso, et al.
Journal of Applied Clinical Medical Physics
|
February 27, 2018
COMP report: CPQR technical quality control guidelines for radiation treatment centers
Kyle E Malkoske, Michelle K Nielsen, Laurent Tantôt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 24, 2013
Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinoma
Jennifer R Diamond, Ravi Salgia, Marileila Varella-Garcia, et al.
Page
of 35